Additionally, dual-specific T cells engineered with Her2-directed CAR and Gp100-specific T-cell receptor repertoire showed durable responses in murine solid tumor models, and transgenic T cells directed against Gp100 showed significant survival advantage in preclinical DIPG models (81, 82). This evidence concerns the gene PMEL and diffuse intrinsic pontine glioma.